Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine™

Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Global Inc. This information contained in this presentation does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer, buy or subscribe for, any securities, nor shall there be any offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. Forward Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Although we believe that we have a reasonable basis for each forward- looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning the following include forward-looking statements: the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and preclinical studies; the potential attributes and benefits of product candidates, including with respect to radioligand selectivity, activity, side effect and tolerability profile and relevant indications; ability to compete with other companies currently marketing or engaged in the development of treatments for relevant indications; the Company’s expected manufacturing and commercial strategy; the size and growth potential of the markets for product candidates and ability to serve those markets; and the rate and degree of market acceptance of product candidates, if approved. In some cases you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumption that, while considered reasonable by POINT and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, factors associated with companies, such as the Company, that are engaged in clinical trials in the pharmaceutical industry, including uncertainty in the timing or results of clinical trials, product acceptance and/or receipt of regulatory approvals for product candidates, risks related to POINT’s ability to successfully develop and launch a commercial product and achieve market acceptance, raise additional funds that may be necessary for the operations of its business and product development, establish manufacturing capacity, manage its operations and potential growth and scale its business, protect its intellectual property, and the potential impact of the COVID-19 pandemic, as well as various other factors beyond management’s control, including general economic conditions. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company undertakes no duty to update these forward-looking statements.

Accelerating Precision MedicineTM POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals 3 POINT’S MISSION Accelerating the discovery, development and global access to life-changing radiopharmaceuticals POINT’S VISION Transforming lives touched by cancer INDUSTRY-LEADING PIPELINE • Prostate cancer (PSMA) program currently in Phase 3 • Pan-cancer (FAP-α) program entering Phase 1 summer 2022 • CanSEEK™ technology to enable significant pipeline expansion IN-HOUSE SUPPLY CHAIN • 100% owned manufacturing infrastructure, capable of supplying North America and Europe • Proprietary radioisotope production FINANCIAL HIGHLIGHTS • Strong balance sheet, with $252.8M in cash and cash equivalents as of September 30, 2021 • Cash runway into the first quarter of 2024 • 93.7M fully diluted shares outstanding HIGHLY EXPERIENCED TEAM • Deep experience in drug manufacturing, drug development and registration • Decades of experience in radiopharmaceuticals PSMA = Prostate-Specific Membrane Antigen, FAP- α = Fibroblast Activation Protein Alpha

Accelerating Precision MedicineTM Radiopharmaceuticals will be a new pillar of oncology treatment with pan-cancer opportunities 4 MOLECULARLY TARGETED RADIATION Radiotherapy is a proven pillar of cancer treatment but lacks precision. By precisely delivering radiation directly to cancer cells with radioligands, the power of radiotherapy can be realized while reducing the off-target effects. OPTIMIZED PATIENT SELECTION Molecular imaging companion diagnostics enable visualization of the therapeutic target to optimize the selection of patients who may best respond to therapy. MONOTHERAPY ACTIVITY AND COMBINATION SYNERGIES Many opportunities exist to develop radiopharmaceuticals as monotherapies and additional options exist to extend the therapeutic uses by combining with other precision treatments, such as DNA damage response and immune checkpoint inhibitors. OUTPATIENT FRIENDLY Modern medical isotopes enable radiopharmaceuticals to be administered outside of hospitals, making them easily accessible globally - over 1,400 outpatient locations in the U.S alone. FEW COMPETITORS + DEEP MOAT PREVENTING NEW ENTRANTS = UNIQUE BUSINESS OPPORTUNITY Scarce input materials combined with a just-in-time supply chain means significantly higher barriers to commercialization as compared to other pharmaceuticals. There is currently no firm realizing high volume economies of scale in radiopharmaceuticals.

Accelerating Precision MedicineTM POINT has assembled one of the most experienced teams in the clinical development and manufacturing of radiopharmaceuticals 5 + 40+ CLINICAL TRIALS 30+ INDS, 30+ CTAS, 10+ INTERNATIONAL TRIALS + 12 APPROVALS 10 NDA/NDSS, 5 ANDA, 1 SNDS, 2 DMFS + 8 GMP RADIOPHARMACEUTICAL FACILITIES 18 FDA INSPECTIONS, 27 HEALTH CANADA INSPECTIONS LEADERSHIP TEAM’S PREVIOUS FIRMS INCLUDE LEADERSHIP TEAM’S ACHIEVEMENTS INCLUDE Accelerating Precision Medicine™ DR. JOE McCANN PhD CEO & Co-Founder BILL DEMERS, FCPA Chief Financial Officer DR. MYRA ROSARIO HERRLE, PhD EVP, Regulatory Affairs DR. NEIL FLESHNER, MD Chief Medical Officer & Co-Founder JUSTYNA KELLY, MSc Chief Operating Officer JESSICA JENSEN, MPH EVP, Clinical Development ALLAN SILBER Executive Chairman & Co-Founder ARI SHOMAIR Chief of Staff TODD HOCKEMEYER EVP, US Manufacturing

Accelerating Precision MedicineTM Novel ligands are greatly expanding the number of cancer indications that can be treated with radiopharmaceuticals 1. Baum et al. J Nucl Med 2016 6 Radioligands enable the precise targeting of cancer by combining a radioisotope, a linker & a targeting moiety that seek cancer cells PSMA is overexpressed on prostate cancer cells A PSMA specific ligand seeks out cancer cells The radioisotope emits ionizing radiation Ionizing radiation kills the tumor cell, while minimizing damage to healthy tissue + + = L I N KE R Radioligand (PNT2002) CANCER CELL LIGAND RADIOISOTOPE PSMA-PET Scan Before Treatment1 PSMA = Prostate Specific Membrane Antigen PSMA-PET Scan After 3 177Lu-PSMA Treatments1 RE C EPTOR

Accelerating Precision MedicineTM New radioisotopes are further enhancing radiopharmaceuticals’ capabilities 7 POINT leverages the unique properties of a variety of medical isotopes. Isotope selection considerations include radiation type, energy emission, and half-life. Many modern radioisotopes can be administered at community-based infusion centers, greatly expanding access. Emission Type Large alpha particles (He atoms) Very small particles (electrons) High energy electrons Half-life 7.2 hours - 10 days 6.6 days 6.9 days Energy 5-9 MeV 50-2,300 keV Up to 100 keV Path Length 40-100 μm (2-10 cells) 0.3-12 mm (10-1,200 cells) 2-500 nm (1/20th of a cell) Energy Transfer 80 keV/μm 0.2 keV/μm 4-26 keV/μm Ac Actinium (225) 89 At Astatine (211) 85 Lu Lutetium (177) 71 Tb Terbium (161) 65 Alpha (α) Decay Auger Electrons Beta (β-) Decay

Accelerating Precision MedicineTM Radiopharmaceuticals offer an extremely broad potential opportunity for combination therapies 8 Monotherapy and expected synergistic MoA with existing therapeutic classes MonotherapyActivation of anti-tumor immunity Sensitization to DNA Damage Response Inhibitors (DDRi) cGAS-STING pathway Antigen visibility Neoantigen load PARP inhibitorsAnti-PD1/CTLA4 Combination Isotopes TLR Agonism ATM/ATR inhibitors CHK1/CHK2 inhibitors Radioligand therapy

Accelerating Precision MedicineTM POINT’s platform overcomes the barriers that have prevented radiopharmaceutical commercialization 9 ManufacturingLate-Stage Programs There are currently no large-scale contract radiopharmaceutical manufacturing facilities Only three therapeutic radioligands currently marketed in the U.S.: Lutathera, Azedra, & Zevalin Isotope Supply Isotopes are a scarce, heavily- regulated raw material that decay within days from manufacturing POINT addressed the major isotope risks POINT built one of the largest radiopharm facilities in the world POINT’s lead asset reports top-line Phase 3 data in mid-2023 Early-Stage Programs Radiopharmaceuticals have historically targeted orphan indications and rare diseases POINT’s pipeline targets high prevalence indications

Accelerating Precision MedicineTM Manufacturing and supply chain are the key success factors: radiopharmaceuticals are made just- in-time with a useable life measured in days 10 POINT’s 100% owned & operated Indianapolis, Indiana manufacturing facility is currently supplying doses for the company’s SPLASH trial. State of the art 80,000 ft2 GMP facility NRC licensed for alpha, beta, gamma and positron emitters Integrated radioisotope production Sterility assurance labs for in-house batch testing Modular capacity, capable of scaling with demand US population within 12 hours, EU & UK within 48 hours β- α γ β+ POINT’s manufacturing facility has the capacity to service high volume indications in North America and Europe.

Accelerating Precision MedicineTM POINT’s Facility 11 POINT’s lutetium-177 and actinium-225 supply chains are industry-leading Internal 177Lu production capability will provide a COGS advantage and supply chain redundancy Redundant 225Ac supply from partners with access to rare Thorium and Radium inputs Ytterbium-176 input material secured in North America Nuclear reactor irradiation network assembled Technology to purify 177Lu at a significant scale POINT’s Facility Thorium-229 (U.S. Department of Energy waste stores) Radium-226 Radium-226 225Ac “milked” from Thorium “cows” 225Ac via electron accelerator 225Ac via proton accelerator Ac Actinium (225) 89 No-carrier-added 177Lu partner No-carrier-added 177Lu manufactured internally No-carrier-added 177Lu partner Thorium- 229 225Ac “milked” from Thorium “cows”

Accelerating Precision MedicineTM POINT is positioned to be a leader in next-generation radiopharmaceuticals 12 Program Target Clinical Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 PSMA 177Lu-PSMA I&T PSMA 177Lu-PSMA I&T SSTR 177Lu-DOTA-TATE FAP-α 177Lu-PNT6555 FAP-α 225Ac-PNT6555 PSMA 225Ac-Not Disclosed Not Disclosed Not Disclosed Not Disclosed Not Disclosed mCRPC*, Pre-Chemo mCRPC*, Post-Chemo, combination w/ J591** Neuroendocrine Tumors (NETs)*** Solid Tumors Expressing FAP Solid Tumors Expressing FAP Not Disclosed Prostate Cancer PNT2002 PNT2003 PNT2004 PNT2001 CanSEEK™ Enabled Programs Not Disclosed PNT2002 PNT2004 POINT's CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, which has branded the technology as pre|CISION™ (an Avacta trademark). * mCRPC: Metastatic castrate-resistant prostate cancer ** Trial sponsored by Weill Medical College of Cornell University (NCT04886986) *** Trial sponsored by the University Health Network (NCT0274374)

Accelerating Precision MedicineTM POINT is creating the future of radiopharmaceuticals with technologies like CanSEEK™, designed to improve the precision and safety of all radioligands Images are renderings, created for explanatory purposes only. The CanSEEKTM technology has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, who has branded the technology as pre|CISIONTM (an Avacta trademark). 13 Salivary Glands Kidneys With CanSEEK™ Minimal delivery to healthy tissue Without CanSEEK™ On-target, off-tissue = healthy tissue damage

Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 14 Balance Sheet $252.8M cash & cash equivalents, as of Sept 30, 2021 Projected Runway Cash to fund operations into the first quarter of 2024 Capital Structure 90.1M Common Shares + 3.6M Options Program Clinical Candidate Indication Timing (Est.) Milestone Completed Manufacturing 177Lu-PSMA I&T mCRPC Q4 2021 IND Amendment to add facility to supply chain 177Lu-PSMA I&T mCRPC Q1 2022 Dosimetry presentation from 27 patient lead-in Upcoming 177Lu-PSMA I&T mCRPC H2 2022 Efficacy and safety data from 27 patient lead-in Mid-2023 Top line data 177Lu-PNT6555 Solid Tumors Expressing FAP Q1 2022 CTA filing Summer 2022 First patient in (Phase 1) 225Ac-Not Disclosed Prostate Cancer H1 2023 IND / CTA filing 177Lu-DOTA-TATE Neuroendocrine Tumors (NETs) Q1 2022 Confirmation of optimal regulatory and commercial pathways PNT2002 PNT2003 PNT2002 PNT2001 PNT2004

Accelerating Precision MedicineTM Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC Top Line Data: Mid-2023

Accelerating Precision MedicineTM PNT2002 is a PSMA-targeted therapy for metastatic Castration-Resistant Prostate Cancer (mCRPC), in an indication with >36,000 post-ARAT pre-chemo patients annually in the US 1. Beauregard et al. SNMMI Mid-Winter Meeting Feb 2022 2. US Patent 11,129,912 Sep 28 2021 16 • Every year in the U.S. 12,000 men are diagnosed with mCRPC and an additional 40,000 progress from earlier stages of the disease o 95% treated o 90% 2nd line progression o 80% overexpress PSMA • PNT2002 uses the PSMA-I&T ligand, which has been administered to >600 patients1 at a range of 2.5-9.2 GBq based on published reports. • POINT’s innovation solved the stability issue of the I&T ligand, which was then protected with unique IP2 around radioactive API and formulation to drive stability of the molecule out to 7 days. T U M O R V O L U M E T IME Localized Therapy Androgen Deprivation Therapy Novel Antiandrogens Chemotherapy PARPi Ra-223 Chemotherapy Immunotherapy Non-metastatic (M0) Metastatic (M1) Castration Sensitive (CSPC) Castration Resistant (CRPC) PNT2002

Accelerating Precision MedicineTM Prostate Specific Membrane Antigen (PSMA) is a clinically-validated therapeutic target, ideal for prostate cancer therapy 1. Hupe MC. et al. 2018. Front. Onc. 2. Pangalos MN. et al. 1999. J. Biol. Chem. 3. Davis M. et al. 2005. PNAS 4. Murphy GP. et al. 2000. Prostate. 5. Liu C. et al. Cancer Med. 6. Ghosh A. et al. 2004. J. Cell. Biochem. 17 • PSMA is over-expressed in the vast majority of prostate cancers (>85%)1, but very limited on normal tissues2. • PSMA is a 750-residue type II transmembrane glycoprotein with glutamate carboxypeptidase activity3 o Expression increases with prostate cancer disease progression and metastasis4 o Expression is associated with poor prognosis in prostate cancer5 • Expression is also upregulated on solid tumor neovasculature6. • There are two FDA-approved PET-PSMA imaging agents (68Ga and 18F) for initial and recurrence of prostate cancer.

Accelerating Precision MedicineTM PNT2002’s Phase 3 Study for mCRPC: The SPLASH Protocol 1. De Bono et al. N Engl J Med 2020; 382:2091-2102 2. Sweeney et al. AACR 2020 18 Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177Lu-PNT2002 PSMA Therapy versus Abiraterone or Enzalutamide After Second-Line Hormonal Treatment (NCT04647526), a multi-center, open label, randomized study. Standard of care in chemo-averse mCRPC are ARATs (abiraterone, enzalutamide) offering rPFS of approx. 4 months based on recent trials1,2 Dosimetry & Safety Run-in (enrollment and dosing COMPLETED) Randomization Expansion (initiated September 2021) Safety and Preliminary Efficacy • AE/SAEs • Dosimetry • Changes in vital signs, clinical labs, ECGs • PSA reduction R a n d o m iz e 2 :1 177Lu-PNT2002 Abiraterone or Enzalutamide 177Lu-PNT2002 Key Eligibility • mCRPC • PSMA-avid PET • Progressed on ARAT therapy • Chemo naïve for mCRPC R a d io g ra p h ic P ro g re s s io n 177Lu-PNT2002 Primary • rPFS Secondary • OR • OS • PK Exploratory • Pain PFS • PSMA PET • PSA PFS • HRQoL N=27 N=260 N=130 SCREENING 6 weeks TREATMENT 32 weeks LONG TERM FOLLOW-UP 5 years, death, or loss to follow up 6.8 GBq Q8w x 4 6.8 GBq Q8w x 4

Accelerating Precision MedicineTM 19 Cumulative Administered Activity SPLASH Trial Lead-In1 (N=27) Median Dose 6.8 GBq / 4 cycles Total Kidneys 19.9 Gy Total Red Marrow 0.91 Gy Total Lacrimal Gland 33.7 Gy Total Salivary Gland 9.15 Gy PNT2002 (PSMA-I&T) Baum2 Median Dose 5.8 (3.6-8.7) GBq / 2 (1-5) cycles Safety 0% AEs led to death or discontinuation Patients with >50% PSA decline 59% Median Radiographic Progression-Free Survival 13.7 months (N=56) Median Overall Survival Not reached at 28 months (N=56) Dosimetry data from SPLASH trial lead-in is in-line with previously published literature, and met pre-defined criteria • Radiation dosimetry of PNT2002 was calculated in 27 patients with mCRPC based on biodistribution data post injection of their first cycle of PNT2002. • Organs receiving the largest absorbed doses were the lacrimal glands at 1.2 Gy/GBq, followed by the kidneys at 0.73 Gy/GBq. • For a cumulative administered activity of 27.2 GBq (4 cycles of 6.8 GBq), the kidneys would receive a cumulative absorbed dose of 19.9 Gy and the red marrow 0.91 Gy. 1. Beauregard et al. SNMMI Mid-Winter Meeting Feb 2022 2. Baum et al. J Nucl Med 2016;57:1006-1013

Accelerating Precision MedicineTM 20 Four DSMB meetings completed to date with no recommended changes to study conduct or protocol FDA agreement to proceed with randomization ahead of schedule in December 2021 Red marrow dosimetry well below critical thresholds enabling the potential opportunity for combination therapy Kidney dosimetry is within range of previously published data of comparable ligands Green Light from DSMB Dosimetry Combination Candidate Low discontinuation rate due to AEs, with myelosuppression lower than published safety data of comparable ligands Safety / Favorable Myelotox Profile Next step: Efficacy and safety from 27 patient lead-in (H2 2022) Summary: PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied

Accelerating Precision MedicineTM Randomization has begun in US and Canada, ongoing EU expansion to expedite accrual 21 Initiate EU Expansion Q4 2021 Start of US Randomization December 2021 Present Dosimetry Data at SNMMI February 2022 NDA Planning and Continued FDA Engagements Q2 2022 – Q3 2023 Top Line Data Mid-2023 As well as: ✓ ✓ ✓

Accelerating Precision MedicineTM Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

Accelerating Precision MedicineTM PNT2003 is a somatostatin receptor targeted treatment for Neuroendocrine cancer (NETs) 1. Oronsky B. et al. 2017, 2. Dasari A. et al. 2017. 23 NETs are heterogeneous tumors that originate in neuroendocrine cells1. • PNT2003 uses the SSTR-targeted DOTA- TATE ligand, also utilized in the currently approved radiopharmaceutical product for the GEP-NETs indication. • POINT has licensed both trial data as well as unique intellectual property from CanProbe which enables the formulation of DOTA-TATE while remaining fully outside of competitors’ patent space. Lung NETs Unknown Primary Other • Medulla • Paraganglia • Adrenal medulla • Ovary Hindgut • Left colon • Rectum Midgut • Jejunum • Ileum • Right colon • Appendiceal Foregut • Stomach • Duodenum Gastroenteropancreatic (GEP-NETs) Non GEP-NETs

Accelerating Precision MedicineTM Somatostatin receptors (SSTRs) are a validated target for NETs therapy 1. Caplin ME. et al. 2014. NEJM 2. Rinke et al. 2009. JCO. 3. Patel YC. et al. 1997. Endocrin. Metabo. 4. Yang SK. et al. 2007. Clin. Exp. Pharm. Phys. 5. Papotti M. et al. 2002. Virch. Arch. 24 SSTRs are ideal targets for NET therapy: • Somatostatin analogs (SSAs) have been developed with anti-secretory and anti-proliferative effects for NET therapy1,2 • Randomized clinical trials with somatostatin analogs have demonstrated efficacy1 SSTRs are a family of G-protein coupled receptors, with 5 receptor subtypes identified3: • The receptors display a high degree of structural conservation across subtypes4 • SSTRs are highly expressed on NETs5 • SSTR2 is generally the most highly expressed receptor in NET5 SSTR

Accelerating Precision MedicineTM PNT2003’s reduced radiation safety burden offers a significant opportunity for differentiation from the currently approved radiopharmaceutical product for the GEP-NETs indication 25 The 177Lu in PNT2003 does not contain long-lived radioactive impurities, resulting in simplified administration of the drug product. Carrier-added 177Lu Contains up to 0.01% metastable 177mLu, a radionuclide with a half-life of 5+ months, forcing clinics to create a costly specialized waste stream required by the NRC1 for disposing waste with a physical half-life >120 days Lu 71 Lutetium (177m) Contains no 177mLu; infrastructure requirements are minimal, same as for PNT2002 PNT2003: No-carrier-added 177Lu Yb 176 Yb 177 Lu 71 Lutetium (177) Yb 70 Ytterbium (176) 6.65d 160.4d Lu 71 Lutetium (177) 6.65d Lu 71 Lutetium (176) Both 177mLu and 177Lu incorporated in drug product Only 177Lu in drug product neutron irradiation (reactor) neutron irradiation (reactor) 1. NRC Part 35.92 Decay-in-storage

Accelerating Precision MedicineTM Neuroendocrine Tumors (NETs) is a large market opportunity; there are multiple potential regulatory pathways available to PNT2003 (DOTA-TATE) 1. Oronsky B. et al. 2017. Neoplasia 2. NETs – SEER 18 3. Dasari A. et al. 2017. JAMA 4. Man D. et al. 2018 26 POINT is currently assessing the regulatory pathways for PNT2003 based on feedback and ongoing discussions with regulatory authorities. US NETs Epidemiology1,2,3,4 Locally advanced + metastatic GEP SSTR+ Diagnosed and Treatable 33,000 PATIENTS 23,000 PATIENTS 16,000 7,000 5,250 4,000 12,000 9,000ANDA pathway Non-GEP NDA pathway Next step: Confirmation of optimal regulatory and commercial pathways

Accelerating Precision MedicineTM Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies

Accelerating Precision MedicineTM The next generation of radiopharmaceuticals will require novel targets, improved ligands, and transformation technologies 28 Novel Targets Improved Ligands Transformational Technologies Pan-cancer approaches Better patient outcomes Enhanced therapeutic windows PNT2004 A best-in-class FAP-targeted radioligand which has compelling pan-cancer therapy potential. PNT2001 Has improved tumor uptake and reduced normal tissue binding relative to current generation ligands. CanSEEKTM Aims to virtually eliminate normal tissue radioligand binding and could provide a new paradigm. PNT2004 PNT2001 CanSEEKTM

Accelerating Precision MedicineTM Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand for Multiple Tumor Types

Accelerating Precision MedicineTM PNT2004 is a best-in-class Fibroblast Activation Protein (FAP-α) targeted radioligand with potential for imaging and therapy 30 An ideal radiopharmaceutical targets and is retained in tumors, while flushing out of tissues absent of the target quickly. Developed in collaboration with Dr. William Bachovchin at Tufts, a leader in designing inhibitors of DASH family proteases including FAP-α, PNT2004 has best-in-class tumor retention and normal tissue clearance, enabling delivery of large doses of tumor killing radiation. 48h Lutetium-177 PNT2004 T U MOR FAP-α The Tumor Microenvironment FAP-α >200x tumor:kidney ratio

Accelerating Precision MedicineTM FAP-α is a compelling pan cancer target for imaging and therapy that is found in >90% of epithelial tumors1 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 2. Jacob M. et al. 2012. Curr. Mol. Med. 3. Mariathasan S, et al. 2018. Nature 4. Domen A. et al. 2021. Cancers 5. Joshi RS. et al. 2021. Cancers. 6. Pure E. et al. 2018. Oncogene 7. Niedermeyer J. et al. 2001. Int J Dev. 8. Dohi O. et al. 2009. Histophatology 9. Kratochwil et al. J Nucl Med 2019; 60:801–805 31 In cancer, Fibroblast Activation Protein-α (FAP) is highly expressed on Cancer Associated Fibroblasts (CAFs)2, which drives tumor progression and resistance to chemo and immunotherapy3,4,5: • FAP is a 170kDa membrane bound prolyl endopeptidase6 • FAP is expressed during development but rarely in adult tissues7 • FAP is upregulated at sites of active tissue remodeling, such as during wound healing2 • FAP is highly upregulated in cancer2, and expressed on tumor cells of mesenchymal origin tumors (sarcoma, mesothelioma)8 9

Accelerating Precision MedicineTM PNT6555 is the lead of the PNT2004 program. 68Ga-PNT6555 biodistribution studies demonstrate fast tumor targeting with little accumulation in normal tissues 32 Rapid renal clearance of excess compound and good tumor retention with low background in other organs. 68Ga-PNT6555 BiodistributionDynamic Imaging 68Ga-PNT6555 Biodistribution at 60 min HEK-mFAP tumor bearing Fox Chase SCID, n=3/timepoint

Accelerating Precision MedicineTM 177Lu-PNT6555 biodistribution studies demonstrate prolonged tumor retention and rapid normal tissue clearance 33 Rapid and persistent tumor targeting beyond 7 days with low retention in normal tissues, with exquisite tumor / kidney ratio. Organ uptake 177Lu-PNT6555 SPECT177Lu-PNT6555 Biodistribution HEK-mFAP tumor bearing Fox Chase SCID, n=3/timepoint

Accelerating Precision MedicineTM 177Lu-PNT6555 shows compelling anti-tumor activity, with mice experiencing long-term survival 34 Tumor Volumes on Day 22Tumor Volumes Kaplan-Meier Survival Curves HEK-mFAP model, n=6/group, single dose treatment in mice with tumors (~200mm 3), ns=not significant, *p<0.05, **p<0.01, ***p<0.001, **** p<0.0001 0 10 20 30 40 50 60 70 80 0 1000 2000 3000 Time post-injection (d) T u m o r v o l u m e ( m m 3 ) Vehicle Precursor 177Lu-PNT6555 (60 MBq) 177Lu-PNT6555 (30 MBq) 177Lu-PNT6555 (15 MBq) 0 1000 2000 3000 4000 5000 T u m o r v o l u m e ( m m 3 ) ns **** **** **** 0 10 20 30 40 50 60 70 80 0 50 100 Time post-injection (d) % S u r v i v a l Vehicle Precursor 177Lu-PNT6555 (60 MBq) 177Lu-PNT6555 (30 MBq) 177Lu-PNT6555 (15 MBq) ns *** *** *** Similar results have been shown with 225Ac-PNT6555

Accelerating Precision MedicineTM PNT2004 is on track for a CTA Submission in Q1 2022 35 Lead selected. IND-enabling efficacy, biodistribution and toxicology studies complete. Additional studies in syngeneic and PDX models underway. Process and method optimization and validation with target complete. Health Authority meetings completed Q4 2021 and Q1 2022, with study start-up ongoing. First patient in summer 2022. NON-CLINICAL CMC CLINICAL & REGULATORY

Accelerating Precision MedicineTM Programs: PNT2001 Next-Generation PSMA Targeting Ligand

Accelerating Precision MedicineTM PNT2001 is a next-generation PSMA radioligand optimized for earlier treatment & delivery of 225Ac 37 1. NPCR and SEER 2005-2016 Registries 2. Scher et al. PLOS ONE, 2015 3. Borofsky et al. Radiology, 2017 4. POINT Primary Market Research, Dec 2020 5. Thoma et al. Nature Reviews Urology, 2020 6. Sweat SD, et al. Urology, 1998 7. Datamonitor 2018 Global Prostate Report T U M O R V O L U M E T IME Localized Therapy Androgen Deprivation Therapy Novel Antiandrogens Chemotherapy PARPi Ra-223 Chemotherapy Immunotherapy Non-metastatic (M0) Metastatic (M1) Castration Sensitive (CSPC) Castration Resistant (CRPC) 28k Patients* = mHSPC (Oligometastatic PC) PNT2002 7k Patients* = Post 177Lu 225Ac mCRPC • PNT2001 could move earlier in treatment by extending the therapeutic window of PSMA radioligand therapy, thereby overcoming the radiation toxicity concerns surrounding current generation PSMA targeted ligands. • A clinical development pathway to move later in treatment in post-177Lu-PSMSA mCRPC is also being considered

Accelerating Precision MedicineTM PNT2001 has linker technology that allows for increased internalization into cells, resulting in increased tumor uptake Unpublished data 38 This profile could result in the same outcomes seen with today’s technology at a lower dose, potentially allowing for a reduction in the radiopharmaceutical dose. 177Lu-PNT2001 T: 14.3%|D/g K: 13.7%|D/g T: 12.4%|D/g K: 11.3%|D/g SPECT/CT Imaging LNCaP tumor-bearing CB17-SCID mice, 24 h p.i., 160 pmol each, n = 2 Improved internalization Improved tumor uptake 177Lu-PSMA-62, LNCaP tumor bearing , CB17-SCID mice (n = 4, t=24 h) Internalization in LNCaP cells (n = 3) relative to [125I]I-BA)KuE reference compound Reduced kidney uptake

Accelerating Precision MedicineTM Unpublished data LNCaP model, n=6/group, single dose treatment in mice with large tumors (~600mm 3), ns=not significant, *p<0.05, **p<0.01, ***p<0.001, **** p<0.0001 39 Next step: IND-enabling studies in 2022 225Ac-PNT2001 shows compelling efficacy as a single dose in pre-clinical tumor models Tumor Volumes on Day 21Tumor Volumes Kaplan-Meier Survival Curves 0 1000 2000 T u m o r v o l u m e (m m 3 ) *** ns ns 0 10 20 30 40 50 60 70 0 50 100 Time post-injection (d) % S u r v iv a l Vehicle Precursor 225 Ac-PNT2001 (20kBq) 225Ac-PNT2001 (40kBq) ns ** ** 0 10 20 30 40 50 60 70 0 1000 2000 Time post-injection (d) T u m o r v o l u m e (m m 3 ) Vehicle Precursor 225 Ac-PNT2001 (20kBq) 225Ac-PNT2001 (40kBq)

Accelerating Precision MedicineTM Programs: CanSEEK™ FAP-α Activated Prodrug Technology Platform

Accelerating Precision MedicineTM Early 225Ac clinical data demonstrates the off-target delivery is limiting usage of next-generation radioisotopes 41 1. Kratochwil, C, et al. J Nucl Med 2016 2. Zacherl, M, et al. J Nucl Med 2020 3. Ruigrok, E, et al. Pharmaceceutics 2019 3 cycles of 9-10 MBq 225Ac-PSMA-617 bimonthly 1 cycle of 6 MBq 225Ac-PSMA-6171 2 cycles of 225Ac-PSMA-I&T (13.4 MBq total)2 3

Accelerating Precision MedicineTM The goal of the CanSEEK™ prodrug technology platform is to improve precision, efficacy and safety of all radioligands 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 42 • CanSEEK™, currently in pre-clinical development, prevents a radioligand from binding to receptors until it has been activated by FAP-α in the tumor microenvironment (TME), potentially preventing off-target delivery, improving therapeutic index, and enabling usage of new isotopes. POINT’s CanSEEKTM has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, who has branded the technology as pre|CISIONTM (an Avacta trademark). …until it reaches FAP-α, which is present in >90% of epithelial tumor microenvironments1… Radioligand CanSEEK™ blocks a Radioligand’s ability to bind to receptors… … then FAP-α cleaves CanSEEK™ away, allowing the radioligand to bind to the tumor’s receptors CanSEEK™ FAP-α FAP-α CanSEEK™ Tumor Microenvironment

Accelerating Precision MedicineTM CanSEEK™ is as a radiopharmaceutical drug platform that enables re-evaluation of known ligands previously set aside due to off-target delivery concerns 43 • By extending the therapeutic index of ligands, CanSEEK™ could also enable the use of emerging medical isotopes like Actinium- 225, which have heightened toxicity concerns due to the type and volume of their energy emissions. Next step: Ongoing pre-clinical studies

Accelerating Precision MedicineTM Summary & Milestones

Accelerating Precision MedicineTM POINT will drive innovation in radiopharmaceuticals by overcoming their current limitations 45 THE FUTURE OF RADIOPHARMACEUTICALS CanSEEK™ prodrug technology in development to increase efficacy and safety Partnering with sources of emerging alpha, beta and auger emitting isotopes to increase potency Programs combining radioligands with other treatment modalities will be a focus By 2025 • Initiated commercial radioligand sales • FAPi program on the path to registration • Multiple next-generation radioligands in clinic • Commercial-scale manufacturing supply chain

Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 46 Program Clinical Candidate Indication Timing (Est.) Milestone Completed Manufacturing 177Lu-PSMA I&T mCRPC Q4 2021 IND Amendment to add facility to supply chain 177Lu-PSMA I&T mCRPC Q1 2022 Dosimetry presentation from 27 patient lead-in Upcoming 177Lu-PSMA I&T mCRPC H2 2022 Efficacy and safety data from 27 patient lead-in Mid-2023 Top line data 177Lu-PNT6555 Solid Tumors Expressing FAP Q1 2022 CTA filing Summer 2022 First patient in (Phase 1) 225Ac-Not Disclosed Prostate Cancer H1 2023 IND / CTA filing 177Lu-DOTA-TATE Neuroendocrine Tumors (NETs) Q1 2022 Confirmation of optimal regulatory and commercial pathways Balance Sheet $252.8M cash & cash equivalents, as of Sept 30, 2021 Projected Runway Cash to fund operations into the first quarter of 2024 Capital Structure 90.1M Common Shares + 3.6M Options PNT2002 PNT2003 PNT2002 PNT2001 PNT2004

Accelerating Precision MedicineTM 47 NASDAQ: PNT Accelerating Precision Medicine™ investors@pointb iopharma.com POINTBiopharma.com